Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.
Ramasamy K, Vij R, Kuter D, Cella D, Durie BGM, Abonour R, Rifkin RM, Ailawadhi S, Lee HC, Cowan AJ, Ho C, Dhanasiri S, Fish S, Yu E, Dhamane AD, Fang J, Marshall TS, Samuel A, Liu L, Katz J, Gu T, Jagannath S. Ramasamy K, et al. Among authors: ailawadhi s. Clin Lymphoma Myeloma Leuk. 2024 Dec 6:S2152-2650(24)02441-8. doi: 10.1016/j.clml.2024.12.002. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39799046
Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration.
Sandahl TB, Soefje SA, Fonseca R, Ailawadhi S, Parrondo R, Lin D, Wu B, Calay ES, Silvert E, Kim N, Carpenter C, Wagner TE, Fowler J, Hester L, Rangarajan N, Murugadoss K, Marshall A, Stoy P, Gifkins D, Lin Y, Kumar S. Sandahl TB, et al. Among authors: ailawadhi s. JCO Oncol Pract. 2024 Dec 20:OP2400489. doi: 10.1200/OP-24-00489. Online ahead of print. JCO Oncol Pract. 2024. PMID: 39705632
Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States.
Ailawadhi S, Cheng M, DerSarkissian M, Dabora J, Young M, Noga SJ, Pi S, Zhang M, Banatwala A, Duh MS, Cherepanov D. Ailawadhi S, et al. J Manag Care Spec Pharm. 2024 Dec;30(12):1431-1441. doi: 10.18553/jmcp.2024.24085. Epub 2024 Sep 9. J Manag Care Spec Pharm. 2024. PMID: 39612251 Free PMC article.
Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the ConnectⓇ MM Registry.
Terebelo HR, Omel J, Wagner LI, Hardin JW, Rifkin RM, Ailawadhi S, Durie BGM, Narang M, Toomey K, Gasparetto CJ, Joshi P, Yu E, Flick ED, Jou YM, Lee HC, Abonour R, Jagannath S. Terebelo HR, et al. Among authors: ailawadhi s. Clin Lymphoma Myeloma Leuk. 2025 Jan;25(1):58-66. doi: 10.1016/j.clml.2024.11.001. Epub 2024 Nov 6. Clin Lymphoma Myeloma Leuk. 2025. PMID: 39603959 Free article.
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.
Ailawadhi S, Lee HC, Omel J, Toomey K, Hardin JW, Gasparetto CJ, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, Joshi P, Jou YM, Mouro J, Yu E, Abonour R. Ailawadhi S, et al. Blood Cancer J. 2024 Nov 11;14(1):198. doi: 10.1038/s41408-024-01177-6. Blood Cancer J. 2024. PMID: 39528478 Free PMC article.
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.
Dimopoulos MA, Migkou M, Bhutani M, Ailawadhi S, Kalff A, Walcott FL, Pore N, Brown M, Wang F, Cheng LI, Kagiampakis I, Williams M, Kinneer K, Wu Y, Jiang Y, Kubiak RJ, Zonder JA, Larsen J, Sirdesai S, Yee AJ, Kumar S. Dimopoulos MA, et al. Among authors: ailawadhi s. Leuk Lymphoma. 2024 Dec;65(12):1789-1800. doi: 10.1080/10428194.2024.2373331. Epub 2024 Oct 15. Leuk Lymphoma. 2024. PMID: 39404476 Free article. Clinical Trial.
Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.
Parrondo RD, LaPlant BR, Elliott J, Fernandez A, Flott CJ, Arrington D, Chapin D, Brown J, Das S, Roy V, Chanan-Khan AA, Ailawadhi S. Parrondo RD, et al. Among authors: ailawadhi s. Blood Cancer J. 2024 Sep 5;14(1):152. doi: 10.1038/s41408-024-01134-3. Blood Cancer J. 2024. PMID: 39237502 Free PMC article. Clinical Trial. No abstract available.
217 results